8-K: Odyssey Health Extends Promissory Note Maturity Dates

Odyssey Health, Inc. has secured extensions for multiple promissory notes, pushing repayment deadlines into 2026 and 2027.

Summary

• Odyssey Health, Inc. entered into several amendments to promissory notes with directors, officers, and accredited investors.
• Four Amendments No. 12 were made to Convertible Promissory Notes originally dated December 21, 2021, and December 22, 2021, with two directors and two officers, extending their maturity to January 31, 2027. One such note had a loan amount of $25,000.00.
• Amendment No. 11 was made to a Convertible Promissory Note with LGH Investments, LLC, originally dated April 5, 2021, extending its maturity to April 30, 2026. This note had a loan amount of $1,050,000.00.
• Amendment No. 5 was made to a Convertible Promissory Note with accredited investor Jonathan Lutz, originally dated February 13, 2024, extending its maturity to January 31, 2027.
• Amendment No. 2 was made to a Promissory Note with accredited investor Peter J. DArruda, originally dated August 14, 2024, extending its maturity to January 31, 2027. This note had a loan amount of $300,000.00.
• The total known principal amount of the extended notes is at least $1,375,000.00, not including the full sum of the four director/officer notes.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as the repeated extensions of debt maturity dates, particularly with related parties, suggest ongoing financial strain and potential liquidity issues for the company.

Positives

• The company successfully negotiated extensions on several promissory notes, providing additional time to meet these financial obligations.
• The extensions demonstrate continued support from key stakeholders, including directors, officers, and accredited investors.

Negatives

• The necessity for repeated extensions on multiple promissory notes suggests ongoing liquidity challenges or an inability to generate sufficient cash flow for timely repayment.
• Reliance on extensions from related parties and accredited investors may indicate difficulty in securing traditional financing under favorable terms.
• The frequent amendments to these notes (e.g., 12th amendment for director/officer notes, 11th for LGH Investments) highlight a pattern of deferred repayment.

Risks

• Continued reliance on short-term financing and repeated extensions poses a risk to the company's long-term financial stability.
• There is a risk that the company may require further extensions or face challenges in repaying these obligations when the new maturity dates arrive.
• The convertible nature of some promissory notes could lead to future share dilution if converted into equity, impacting existing shareholders.
• The ongoing need for debt extensions may signal underlying operational or financial performance issues.

Future Outlook

The company's future outlook, as implied by these extensions, suggests a continued focus on managing existing debt obligations and potentially seeking further financing or operational improvements to meet these extended deadlines. No explicit forward-looking guidance on revenue or profitability was provided.

Management Comments

• J. Michael Redmond, President and Chief Executive Officer, signed the amendments on behalf of Odyssey Health, Inc., acknowledging acceptance and agreement of the extensions.
• Lucas Hoppel, Managing Member, signed the Amendment #11 on behalf of LGH Investments, LLC.
• Jon Lutz signed Amendment No. 5 as an accredited investor.
• Peter DArruda signed Amendment No. 2 as an accredited investor.

Industry Context

StockSavvy.ai notes that repeated extensions of debt maturity dates, particularly with related parties, are often observed in smaller, developing companies or those facing significant operational or financial headwinds. This practice can be a stop-gap measure to maintain liquidity but may also signal challenges in securing more conventional or long-term financing. In the broader industry, companies typically aim to refinance or repay debt on schedule, and frequent extensions can raise questions about financial health compared to more established peers.

Comparison to Industry Standards

• Compared to industry standards, frequent and multiple extensions of promissory notes, especially with insiders, are not typical for financially robust companies. Well-capitalized companies generally repay or refinance debt without such repeated deferrals.
• For example, a mature biotech company like Amgen or Gilead Sciences would typically manage debt through established credit facilities or bond markets, not through numerous amendments to individual promissory notes with directors and accredited investors.
• Smaller, early-stage companies, particularly in sectors with long development cycles, might exhibit similar patterns, but the sheer number of amendments (e.g., 12th amendment) suggests a prolonged reliance on this form of financing management, which is less common for companies aiming for rapid growth or market leadership without significant external capital injections.

Related Party Transactions

• The company entered into four Amendments No. 12 to Convertible Promissory Notes with two directors and two officers of the company.
• The company entered into Amendment No. 11 to a Convertible Promissory Note with LGH Investments, LLC, which is likely a related party or significant investor.
• The company entered into Amendment No. 5 to a Convertible Promissory Note with Jonathan Lutz, an accredited investor.
• The company entered into Amendment No. 2 to a Promissory Note with Peter J. DArruda, an accredited investor.

Stakeholder Impact

• Shareholders: Potential for future dilution if convertible notes are converted into equity. The ongoing need for extensions may also raise concerns about the company's financial health and stock performance.
• Creditors (Note Holders): The extensions provide more time for repayment but also prolong their exposure to the company's financial performance. The repeated nature of extensions might increase perceived risk.
• Management/Directors: Those who are also note holders are directly impacted by the extensions, indicating their continued financial support and belief in the company, but also their exposure to its financial challenges.

Next Steps

• The company will need to address the repayment of the LGH Investments, LLC note by April 30, 2026.
• The company will need to address the repayment of the notes with directors/officers, Jonathan Lutz, and Peter J. DArruda by January 31, 2027.

Key Dates

Recommendation

The repeated and numerous extensions of promissory notes, particularly with insiders and accredited investors, signal persistent financial distress and an inability to meet obligations in a timely manner. This pattern suggests underlying operational or liquidity issues that are not being resolved, increasing the risk profile for investors. While extensions offer temporary relief, they do not address the fundamental problems, making the stock a high-risk proposition with limited upside potential until a clear path to sustainable profitability and debt repayment is demonstrated.

Keywords

Promissory Note Extension, Debt Maturity, Convertible Promissory Note, SEC 8-K, Odyssey Health, Financial Obligation, Liquidity, Related Party Transaction